Gaopeng Song
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Gaopeng Song has a total of 162 co-authors. Here are the top co-authors by number of shared publications:
- Shuwen Liu
Southern Medical University
19 shared publications Sumei Li
College of Basic Medicine and Public Hygiene, Jinan University, Guangzhou 510632, China
12 shared publications- Zi-Ning Cui
State Key Laboratory of Green Pesticide, Integrative Microbiology Research Centre, Guangdong Province Key Laboratory of Microbial Signals and Disease Control, College of Plant Protection, South China Agricultural University, Guangzhou 510642, China
9 shared publications Hui Li
College of Materials and Energy, South China Agricultural University, Guangzhou, 510642, China
8 shared publicationsMingjian Liu
National Key Laboratory of Green Pesticide, College of Materials and Energy, South China Agricultural University, Guangzhou, 510642, China
8 shared publicationsYixian Liao
Key Laboratory for Biobased Materials and Energy of Ministry of Education, College of Materials and Energy, South China Agricultural University, Guangzhou 510642, China
7 shared publications
Latest Publications
- Open Access
- 7 October 2026
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (10)
A novel ursodeoxycholic acid derivative exhibits broad-spectrum antiviral activity against influenza A virus and coronaviruses by multiphasic disruption of the viral life cycle
Seasonal influenza virus and human coronaviruses (HCoVs) represent persistent threats to global public health, with current antiviral agents limited by narrow-spectrum activity and the emergence of drug resistance. Multi-stage and multi-target antiviral agents enhance therapeutic efficacy and overcome drug resistance versus single-target therapies by inhibiting multiple key steps of the viral life cycle, such as entry, replication, and release. Here, we characterize a novel ursodeoxycholic acid (UCDA) derivative (U-BSA) as a broad-spectrum antiviral candidate effective against influenza A viruses (H1N1 and H3N2), HCoVs (including HCoV-OC43 and other pseudovirus models), and respiratory syncytial virus (RSV). In vitro , U-BSA exhibited inhibitory activity against H1N1 (half-maximal effective concentration [EC 50 ] = 4.10 µM; selectivity index [SI] > 50), H3N2 (EC 50 = 2.41 µM, SI > 40), HCoV-OC43 (EC₅₀ = 9.66 µM, SI > 20), and RSV (EC 50 = 6.01 µM, SI > 12). Furthermore, U-BSA conferred significant protection in a lethal influenza infection model in vivo . Mechanistic studies demonstrated that U-BSA interferes with multiple viral life cycles: it disrupts viral attachment, inhibits entry by blocking endosomal acidification, and suppresses virion release. U-BSA rescues virus-induced membrane lipid disorder, revealing that modulation of host membrane homeostasis serves as a critical upstream mechanism underlying its multiphasic antiviral inhibition. This multi-target mode of action represents a significant advance in antiviral strategy, highlighting U-BSA as a promising candidate for developing broad-spectrum antivirals against pan-respiratory virus.
- 7 October 2026
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (10)
Open AccessA novel ursodeoxycholic acid derivative exhibits broad-spectrum antiviral activity against influenza A virus and coronaviruses by multiphasic disruption of the viral life cycle
Seasonal influenza virus and human coronaviruses (HCoVs) represent persistent threats to global public health, with current antiviral agents limited by narrow-spectrum activity and the emergence of drug resistance. Multi-stage and multi-target antiviral agents enhance therapeutic efficacy and overcome drug resistance versus single-target therapies by inhibiting multiple key steps of the viral life cycle, such as entry, replication, and release. Here, we characterize a novel ursodeoxycholic acid (UCDA) derivative (U-BSA) as a broad-spectrum antiviral candidate effective against influenza A viruses (H1N1 and H3N2), HCoVs (including HCoV-OC43 and other pseudovirus models), and respiratory syncytial virus (RSV). In vitro , U-BSA exhibited inhibitory activity against H1N1 (half-maximal effective concentration [EC 50 ] = 4.10 µM; selectivity index [SI] > 50), H3N2 (EC 50 = 2.41 µM, SI > 40), HCoV-OC43 (EC₅₀ = 9.66 µM, SI > 20), and RSV (EC 50 = 6.01 µM, SI > 12). Furthermore, U-BSA conferred significant protection in a lethal influenza infection model in vivo . Mechanistic studies demonstrated that U-BSA interferes with multiple viral life cycles: it disrupts viral attachment, inhibits entry by blocking endosomal acidification, and suppresses virion release. U-BSA rescues virus-induced membrane lipid disorder, revealing that modulation of host membrane homeostasis serves as a critical upstream mechanism underlying its multiphasic antiviral inhibition. This multi-target mode of action represents a significant advance in antiviral strategy, highlighting U-BSA as a promising candidate for developing broad-spectrum antivirals against pan-respiratory virus.
- Open Access
The Emerging Promise of Pentacyclic Triterpenoid Derivatives as Novel Antiviral Agents Against SARS-CoV-2 Variants
The continuous emergence of SARS-CoV-2 variants, especially the Omicron strain with its heightened transmissibility, has posed ongoing challenges to the efficacy of existing vaccine and drug regimens. This situation highlights the pressing demand for antiviral drugs employing novel mechanisms of action. Pentacyclic triterpenoids (PTs), a structurally varied group of compounds derived from plants, exhibit both antiviral and anti-inflammatory activities, making them attractive candidates for further therapeutic development. These natural products, along with their saponin derivatives, show broad-spectrum inhibitory effects against multiple SARS-CoV-2 variants (from Alpha to Omicron) via interactions with multiple targets, such as the spike protein, main protease (Mpro), RNA-dependent RNA polymerase (RdRp), and inflammatory signaling pathways. This review consolidates recent findings on PTs and their saponins, emphasizing their influence on the key structural features required for inhibiting viral attachment, membrane fusion, reverse transcription, and protease function. We systematically summarized the structure–activity relationships and their antiviral results of PTs based on different target proteins in existing studies. Furthermore, this work points toward new strategies for designing multi-target PT-based inhibitors with improved efficacy against Omicron and future variants.
Open AccessThe Emerging Promise of Pentacyclic Triterpenoid Derivatives as Novel Antiviral Agents Against SARS-CoV-2 Variants
The continuous emergence of SARS-CoV-2 variants, especially the Omicron strain with its heightened transmissibility, has posed ongoing challenges to the efficacy of existing vaccine and drug regimens. This situation highlights the pressing demand for antiviral drugs employing novel mechanisms of action. Pentacyclic triterpenoids (PTs), a structurally varied group of compounds derived from plants, exhibit both antiviral and anti-inflammatory activities, making them attractive candidates for further therapeutic development. These natural products, along with their saponin derivatives, show broad-spectrum inhibitory effects against multiple SARS-CoV-2 variants (from Alpha to Omicron) via interactions with multiple targets, such as the spike protein, main protease (Mpro), RNA-dependent RNA polymerase (RdRp), and inflammatory signaling pathways. This review consolidates recent findings on PTs and their saponins, emphasizing their influence on the key structural features required for inhibiting viral attachment, membrane fusion, reverse transcription, and protease function. We systematically summarized the structure–activity relationships and their antiviral results of PTs based on different target proteins in existing studies. Furthermore, this work points toward new strategies for designing multi-target PT-based inhibitors with improved efficacy against Omicron and future variants.
- 12 August 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 299, 118058
Discovery and optimization of OA amide derivatives containing a trisubstituted -hydroxyproline fragment as novel Omicron fusion inhibitors
- 12 August 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 299, 118058
Discovery and optimization of OA amide derivatives containing a trisubstituted -hydroxyproline fragment as novel Omicron fusion inhibitors
- Open Access
- 29 May 2025
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 15 (8) , 4156-4173
A novel C-3-substituted oleanolic acid benzyl amide derivative exhibits therapeutic potential against influenza A by targeting PA–PB1 interactions and modulating host macrophage inflammation
- 29 May 2025
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 15 (8) , 4156-4173
Open AccessA novel C-3-substituted oleanolic acid benzyl amide derivative exhibits therapeutic potential against influenza A by targeting PA–PB1 interactions and modulating host macrophage inflammation
- Open Access
- 2 January 2025
- Published by MDPI AG in Applied Microbiology
- Vol. 5 (1) , 2
Purification and Identification of an Antimicrobial Protein from Bacillus stercoris TY-12 and Its Biocontrol Functions Against Ralstonia solanacearum
Ralstonia solanacearum is a bacterial pathogen that causes bacterial wilt in plants, resulting in significant economic losses worldwide. Biological control that mainly utilizes Bacillus spp. is one of the most effective methods to prevent this disease. In this work, a strain of Bacillus stercoris TY-12 with an obvious antagonism effect on R. solanacearum was screened, and the inhibition diameter against R. solanacearum reached 2.18 cm by the plate antagonism test. Furthermore, an antimicrobial protein was isolated and purified from the fermentation supernatant of TY-12. The LC-MS/MS analysis results indicated that the purified antimicrobial protein is a member of the M42 family metallopeptidase with a molecular weight of approximately 40 kDa and named MP-TY12. After co-culture with MP-TY12 for 4 h, the cell surface of R. solanacearum was disrupted under SEM, indicating that MP-TY12 may inhibit R. solanacearum growth by enzymatically cleaving peptide bonds within the cell wall or membrane structure via hydrolysis. To evaluate the potential application of TY-12 in disease control during crop production, the biocontrol efficacy of TY-12 on the capsicum infected by R. solanacearum was investigated and achieved 84.18%. The growth promotion tests showed that the dry weight, fresh weight, stem diameter, stem length, root length, and the chlorophyll content of capsicum using TY-12 was obviously increased compared to the blank control. It is suggested that TY-12 could be used as a new biocontrol microbial strain in crop production and MP-TY12 might be developed as an antimicrobial agent.
- 2 January 2025
- Published by MDPI AG in Applied Microbiology
- Vol. 5 (1) , 2
Open AccessPurification and Identification of an Antimicrobial Protein from Bacillus stercoris TY-12 and Its Biocontrol Functions Against Ralstonia solanacearum
Ralstonia solanacearum is a bacterial pathogen that causes bacterial wilt in plants, resulting in significant economic losses worldwide. Biological control that mainly utilizes Bacillus spp. is one of the most effective methods to prevent this disease. In this work, a strain of Bacillus stercoris TY-12 with an obvious antagonism effect on R. solanacearum was screened, and the inhibition diameter against R. solanacearum reached 2.18 cm by the plate antagonism test. Furthermore, an antimicrobial protein was isolated and purified from the fermentation supernatant of TY-12. The LC-MS/MS analysis results indicated that the purified antimicrobial protein is a member of the M42 family metallopeptidase with a molecular weight of approximately 40 kDa and named MP-TY12. After co-culture with MP-TY12 for 4 h, the cell surface of R. solanacearum was disrupted under SEM, indicating that MP-TY12 may inhibit R. solanacearum growth by enzymatically cleaving peptide bonds within the cell wall or membrane structure via hydrolysis. To evaluate the potential application of TY-12 in disease control during crop production, the biocontrol efficacy of TY-12 on the capsicum infected by R. solanacearum was investigated and achieved 84.18%. The growth promotion tests showed that the dry weight, fresh weight, stem diameter, stem length, root length, and the chlorophyll content of capsicum using TY-12 was obviously increased compared to the blank control. It is suggested that TY-12 could be used as a new biocontrol microbial strain in crop production and MP-TY12 might be developed as an antimicrobial agent.
- 20 March 2024
- Vol. 44 (3) , 474-483
马铃薯三糖甘草次酸衍生物通过抑制SARS-CoV-2进入靶细胞作为潜在的小分子新冠病毒融合抑制剂
研究马铃薯三糖甘草次酸衍生物能否通过抑制SARS-CoV-2进入靶细胞,作为潜在的小分子新冠病毒融合抑制剂。 以天然SARS-CoV-2进入抑制剂甘草酸为先导化合物,利用活性亚结构的拼合原理等设计并合成了系列马铃薯三糖甘草次酸衍生物。利用SARS-CoV-2假病毒体外细胞感染模型,检测该系列甘草次酸衍生物的体外抗SARS-CoV-2活性;利用表面等离子共振技术及假病毒模型寻找先导化合物1b的抗病毒作用靶点;利用SARS-CoV-2 S蛋白介导的细胞-细胞融合体系,检测先导化合物1b是否作用于SARS-CoV-2病毒入侵宿主的膜融合过程;基于分子对接与定点突变技术,确定先导化合物1b与S蛋白的作用模式等。 先导化合物1b对SARS-CoV-2奥密克戎假病毒有显著抑制作用,EC50值为3.28 μmol/L(P < 0.05),对其它SARS-CoV-2变异株假病毒有广谱抗病毒活性。细胞-细胞膜融合实验显示1b能够抑制合胞体的形成。分子对接预测先导化合物1b可与S1与S2亚基交界处的空腔中的Glu309、Ser305、Arg765、Lys964等多个保守氨基酸残基产生氢键作用,亲和力为-8.6 kcal/mol。化合物1b在10、5、2.5、1.25 μmol/L时对Arg765、Lys964、Glu309和Leu303突变后的假病毒的抑制活性显著降低(P < 0.01)。 马铃薯三糖甘草次酸衍生物能够靶向作用于S蛋白,特异性干扰病毒-细胞膜融合阶段,继而发挥抗SARS-CoV-2感染的作用,是一类结构新颖的小分子SARS-CoV-2融合抑制剂。
- 20 March 2024
- Vol. 44 (3) , 474-483
马铃薯三糖甘草次酸衍生物通过抑制SARS-CoV-2进入靶细胞作为潜在的小分子新冠病毒融合抑制剂
研究马铃薯三糖甘草次酸衍生物能否通过抑制SARS-CoV-2进入靶细胞,作为潜在的小分子新冠病毒融合抑制剂。 以天然SARS-CoV-2进入抑制剂甘草酸为先导化合物,利用活性亚结构的拼合原理等设计并合成了系列马铃薯三糖甘草次酸衍生物。利用SARS-CoV-2假病毒体外细胞感染模型,检测该系列甘草次酸衍生物的体外抗SARS-CoV-2活性;利用表面等离子共振技术及假病毒模型寻找先导化合物1b的抗病毒作用靶点;利用SARS-CoV-2 S蛋白介导的细胞-细胞融合体系,检测先导化合物1b是否作用于SARS-CoV-2病毒入侵宿主的膜融合过程;基于分子对接与定点突变技术,确定先导化合物1b与S蛋白的作用模式等。 先导化合物1b对SARS-CoV-2奥密克戎假病毒有显著抑制作用,EC50值为3.28 μmol/L(P < 0.05),对其它SARS-CoV-2变异株假病毒有广谱抗病毒活性。细胞-细胞膜融合实验显示1b能够抑制合胞体的形成。分子对接预测先导化合物1b可与S1与S2亚基交界处的空腔中的Glu309、Ser305、Arg765、Lys964等多个保守氨基酸残基产生氢键作用,亲和力为-8.6 kcal/mol。化合物1b在10、5、2.5、1.25 μmol/L时对Arg765、Lys964、Glu309和Leu303突变后的假病毒的抑制活性显著降低(P < 0.01)。 马铃薯三糖甘草次酸衍生物能够靶向作用于S蛋白,特异性干扰病毒-细胞膜融合阶段,继而发挥抗SARS-CoV-2感染的作用,是一类结构新颖的小分子SARS-CoV-2融合抑制剂。
- 18 January 2024
- Published by Elsevier in Bioorganic Chemistry
- Vol. 144, 107139
Optimization and biological evaluation of l-DOPA derivatives as potent influenza PAN endonuclease inhibitors with multi-site binding characteristics
- 18 January 2024
- Published by Elsevier in Bioorganic Chemistry
- Vol. 144, 107139
Optimization and biological evaluation of l-DOPA derivatives as potent influenza PAN endonuclease inhibitors with multi-site binding characteristics
- 18 September 2023
- Published by Elsevier in Bioorganic Chemistry
- Vol. 141, 106871
Derivative of cinnamic acid inhibits T3SS of Xanthomonas oryzae pv. oryzae through the HrpG-HrpX regulatory cascade
- 18 September 2023
- Published by Elsevier in Bioorganic Chemistry
- Vol. 141, 106871
Derivative of cinnamic acid inhibits T3SS of Xanthomonas oryzae pv. oryzae through the HrpG-HrpX regulatory cascade
- 15 May 2023
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 256, 115463
Optimization, and biological evaluation of 3-O-β-chacotriosyl betulinic acid amide derivatives as novel small-molecule Omicron
- 15 May 2023
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 256, 115463
Optimization, and biological evaluation of 3-O-β-chacotriosyl betulinic acid amide derivatives as novel small-molecule Omicron
- 15 March 2023
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 310, 116349
Kunxian capsule alleviates renal damage by inhibiting the JAK1/STAT1 pathway in lupus nephritis
- 15 March 2023
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 310, 116349
Kunxian capsule alleviates renal damage by inhibiting the JAK1/STAT1 pathway in lupus nephritis